Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice
Open accessAbstract
One recent promising development in the modification of drug formulations to improve chemotherapy is the use of a liposome-mediated drug delivery system. The efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes were evaluated by injecting liposomal drugs and free drugs into tuberculous mice twice a week for 6 weeks. Liposome-encapsulated drugs at and below therapeutic concentrations were more effective than free drugs against tuberculosis, as evaluated on the basis of CFUs detected, organomegaly, and histopathology. Furthermore, liposomal drugs had marginal hepatotoxicities as determined from the levels of total bilirubin and hepatic enzymes in serum. The elimination of mycobacteria from the liver and spleen was also higher with liposomal drugs than with free drugs. The encapsulation of antitubercular drugs in lung-specific stealth liposomes seems to be a promising therapeutic approach for the chemotherapy of tuberculosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This approach reduces systemic and local toxicity and provides better results than uncoated formulations.
“This approach reduces systemic and local toxicity and provides better results than uncoated formulations.212”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [212]
Macrophage-specific ligands such as MBSA, O-SAP, and DCP facilitate the preferential accumulation of formulations in lung macrophages.
“Macrophage-specific ligands such as MBSA, O-SAP, and DCP facilitate the preferential accumulation of formulations in lung macrophages.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [212]
Cites
Lopez‐Berestein, G., Mehta, R. T., Hopfer, R. L., Mills, K., Kasi, L. P., Mehta, K., Fainstein, V., Luna, M. A., Hersh, E. M., & Juliano, R. L. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303 · see citing works
Deol, P., & Khuller, G. K. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00088-8 · Cited by 160 · see citing works
Self-citationParthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150 · see citing works
Horowitz, A. T., Barenholz, Y., & Gabizón, A. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90084-y · Cited by 139 · see citing works
Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice
Klemens, S. P., Cynamon, M. H., Swenson, C. E., & Ginsberg, R. S. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.967 · Cited by 120 · see citing works
Drug Treatment of Tuberculosis - 1992
Davidson, P. T., & Le, H. Q. (1992) · Drugs · doi:10.2165/00003495-199243050-00003 · Cited by 112 · see citing works
Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug
Alving, C. R., Steck, E. A., Hanson, W. L., Loizeaux, P. S., Chapman, W. L., & Waits, V. B. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90270-9 · Cited by 94 · see citing works
Mechanisms of pathogenicity in mycobacteria
Rastogi, N., & David, H. L. (1988) · Biochimie · doi:10.1016/0300-9084(88)90272-6 · Cited by 88 · see citing works
Majumdar, S., Flasher, D., Friend, D. S., NASSOS, P. S., Yajko, D. M., HADLEY, W. K., & Düzgüneş, N. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2808 · Cited by 86 · see citing works
Mehta, R. T., Hopfer, R. L., Gunner, L. A., Juliano, R. L., & Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1897 · Cited by 82 · see citing works
Alving, C. R., Steck, E. A., Chapman, W. L., Waits, V. B., Hendricks, L. D., Swartz, G. M., & Hanson, W. L. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90207-6 · Cited by 75 · see citing works
Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice
Cynamon, M. H., Swenson, C. E., Palmer, G. S., & Ginsberg, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.8.1179 · Cited by 60 · see citing works
Aging and Hepatotoxicity of Isoniazid and Rifampin in Pulmonary Tuberculosis
den Brande, P. V., Steenbergen, W. V., Vervoort, G., & DEMEDTS, M. G. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.5.7582317 · Cited by 56 · see citing works
Vladimirsky, M. A., & Ga, L. (1982) · PubMed · Cited by 56 · see citing works
Nightingale, S. D., Saletan, S., Swenson, C. E., Lawrence, A. J., Watson, D., Pilkiewicz, F. G., Silverman, E. G., & Cal, S. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1869 · Cited by 54 · see citing works
Saito, H., & Tomioka, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.4.429 · Cited by 50 · see citing works
The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis
Orozco, L. C., Quintana, F. O., Beltrán, R. M., de Moreno, I. U., Wasserman, M. M., & Rodriguez, G. (1986) · Tubercle · doi:10.1016/0041-3879(86)90002-4 · Cited by 49 · see citing works
Crofton, J. (1960) · BMJ · doi:10.1136/bmj.2.5196.449 · Cited by 47 · see citing works
Medda, S., Mukherjee, S., Das, N., Naskar, K., Sb, M., & Basu, M. (1993) · Biotechnology and Applied Biochemistry · doi:10.1111/j.1470-8744.1993.tb00231.x · Cited by 25 · see citing works
Liposomal Hamycin: Reduced Toxicity and Improved Antifungal Efficacy In Vitro and In Vivo
Mehta, R. T., McQueen, T. J., Keyhani, A., & Lopez‐Berestein, G. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.5.1003 · Cited by 21 · see citing works
A simple technique for entrapping rifampicin and isoniazid into liposomes
Wasserman, M. M., Beltrán, R. M., Quintana, F. O., Mendoza, P. M., Orozco, L. C., & Rodriguez, G. (1986) · Tubercle · doi:10.1016/0041-3879(86)90001-2 · Cited by 19 · see citing works
Pancholi, P., VINAYAK, V. K., & Khuller, G. K. (1989) · Journal of Medical Microbiology · doi:10.1099/00222615-29-2-131 · Cited by 17 · see citing works
Self-citation
Flagged first, then by citations
1 of the 23 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Recent advances in hydrogel based drug delivery systems for the human body
Vashist, A., Vashist, A., Gupta, Y. K., & Ahmad, S. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21016b · Cited by 499 · see citing works
Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections
Abed, N., & Couvreur, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.009 · Cited by 354 · see citing works
Nanoparticle approaches against bacterial infections
Gao, W., Thamphiwatana, S., Angsantikul, P., & Zhang, L. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1282 · Cited by 351 · see citing works
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264 · see citing works
Delivery systems to increase the selectivity of antibiotics in phagocytic cells
Briones, E., Colino, C. I., & Lanao, J. M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.027 · Cited by 226 · see citing works
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201 · see citing works
Pulmonary drug delivery systems for tuberculosis treatment
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.009 · Cited by 185 · see citing works
Nanotechnology-Based Approach in Tuberculosis Treatment
Nasiruddin, M., Neyaz, M. K., & Das, S. (2017) · Tuberculosis Research and Treatment · doi:10.1155/2017/4920209 · Cited by 177 · see citing works
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164 · see citing works
Suarez, S., O’Hara, P. J., Kazantseva, M., Newcomer, C. E., Hopfer, R. L., McMurray, D. N., & Hickey, A. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094112861 · Cited by 159 · see citing works
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2006) · Journal of drug targeting · doi:10.1080/10611860600834375 · Cited by 155 · see citing works
Liposomal Formulations for Inhalation
Cipolla, D. C., Gonda, I., & Chan, H. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.71 · Cited by 153 · see citing works
Designing of ‘intelligent’ liposomes for efficient delivery of drugs
Voinea, M., & Simionescu, M. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00450.x · Cited by 152 · see citing works
Tuftsin-bearing liposomes in treatment of macrophage-based infections
Agrawal, A. K., & Gupta, C. M. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00061-7 · Cited by 134 · see citing works
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects
Ain, Q. U. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg165 · Cited by 124 · see citing works
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123 · see citing works
Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans
Cipolla, D. C., Shekunov, B. Y., Blanchard, J., & Hickey, A. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.001 · Cited by 123 · see citing works
Liposomes as Drug Delivery Systems for The Treatment of TB
Pinheiro, M., Lúcio, M., Lima, J. L. F. C., & Reis, S. (2011) · Nanomedicine · doi:10.2217/nnm.11.122 · Cited by 115 · see citing works
Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., & Barrow, W. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2682 · Cited by 113 · see citing works
Changsan, N., Chan, H., Separovic, F., & Srichana, T. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21441 · Cited by 108 · see citing works
Giau, V. V., An, S. S. A., & Hulme, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s190577 · Cited by 107 · see citing works
Labana, S., Pandey, R., Sharma, S., & Khuller, G. K. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00175-9 · Cited by 101 · see citing works
Self-citationCarriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies
Osman, N., Kaneko, K., Carini, V., & Saleem, I. Y. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1502267 · Cited by 93 · see citing works
Dua, K., Rapalli, V. K., Shukla, S. D., Singhvi, G., Shastri, M. D., Chellappan, D. K., Satija, S., Mehta, M., Gulati, M., Pinto, T. D. J. A., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.101 · Cited by 92 · see citing works
Nanostructured drug delivery for better management of tuberculosis
Kaur, I. P., & Singh, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.009 · Cited by 89 · see citing works
Dutt, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.6.829 · Cited by 88 · see citing works
Present status of nanoparticle research for treatment of Tuberculosis
Shegokar, R., Shaal, L. A., & Mitri, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3m59p · Cited by 87 · see citing works
Bhandari, R., & Pal, K. I. (2013) · Current Nanoscience · doi:10.2174/1573413711309020008 · Cited by 83 · see citing works
Liposomal antibiotics for the treatment of infectious diseases
Alhariri, M., Azghani, A. O., & Omri, A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.822860 · Cited by 81 · see citing works
Nanoparticle based Drug Delivery Systems for Treatment of Infectious Diseases
Salouti, M., & Ahangari, A. (2014) · InTech eBooks · doi:10.5772/58423 · Cited by 78 · see citing works
Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation
Justo, O. R., & Moraes, Â. M. (2003) · Drug Delivery · doi:10.1080/713840401 · Cited by 77 · see citing works
Chimote, G., & Banerjee, R. (2010) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31608 · Cited by 75 · see citing works
Liposome-Encapsulated Antibiotics
Salem, I. I., Flasher, D., & Düzgüneş, N. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91015-x · Cited by 68 · see citing works
Mansilha, C., Gameiro, P., PRIETO, M. J. E., & de Castro, B. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00528-7 · Cited by 66 · see citing works
Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety
El-Ridy, M. S., Yehia, S. A., Kassem, M. A., Mostafa, D. M., Nasr, E. A., & Asfour, M. H. (2013) · Drug Delivery · doi:10.3109/10717544.2013.868556 · Cited by 64 · see citing works
Prabakaran, D. S., Singh, P., Jaganathan, K. S., & Vyas, S. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.11.013 · Cited by 62 · see citing works
Patomchaiviwat, V., Paeratakul, O., & Kulvanich, P. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-008-9152-7 · Cited by 62 · see citing works
Niosomal encapsulation of the antitubercular drug, pyrazinamide
El-Ridy, M. S., Abdelbary, A., Nasr, E. A., Khalil, R. M., Mostafa, D. M., El-Batal, A. I., & El-Alim, S. H. A. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.560605 · Cited by 59 · see citing works
(2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70011-8 · Cited by 58 · see citing works
Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Gaspar, M. M., Cruz, A., Fraga, A. G., Castro, A. G., Cruz, M. E. M., & Pedrosa, J. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783955629 · Cited by 58 · see citing works
Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey, R., & Khuller, G. K. (2006) · PubMed · Cited by 56 · see citing works
Self-citation(2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70024-6 · Cited by 54 · see citing works
Advances in nanotechnology for diagnosis and treatment of tuberculosis
Banyal, S., Malik, P., Tuli, H. S., & Mukherjee, T. K. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835eff08 · Cited by 53 · see citing works
Hussain, A., Singh, S., Das, S. S., AnjiReddy, K., Karpagam, S., & Shakeel, F. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190201144815 · Cited by 52 · see citing works
Tuberculosis: from molecular pathogenesis to effective drug carrier design
Dube, D., Agrawal, G. P., & Vyas, S. P. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.012 · Cited by 50 · see citing works
Justo, O. R., & Moraes, Â. M. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055092 · Cited by 50 · see citing works
Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages
Chono, S., Kaneko, K., Yamamoto, E. M., Togami, K., & Morimoto, K. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903099744 · Cited by 49 · see citing works
Peng, X., Li, Y., Yang, L., Mao, Y.-Q., Yang, H., Liu, J., Zhang, D., Chen, L.-J., & Wei, Y.-Q. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-46 · Cited by 48 · see citing works
Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach
Mazlan, M. K. N., Tazizi, M. H. D. M., Ahmad, R., Noh, M. A. A., Bakhtiar, A., Wahab, H. A., & Gazzali, A. M. (2021) · Antibiotics · doi:10.3390/antibiotics10080908 · Cited by 46 · see citing works
Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections
Xu, K., Liang, Z. C., Ding, X., Hu, H., Liu, S., Nurmik, M., Bi, S., Hu, F.-S., Ji, Z., Ren, J., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700509 · Cited by 44 · see citing works
Sciolla, F., Truzzolillo, D., Chauveau, E., Trabalzini, S., Marzio, L. D., Carafa, M., Marianecci, C., Sarra, A., Bordi, F., & Sennato, S. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112054 · Cited by 43 · see citing works
Changsan, N., Nilkaeo, A., Pungrassami, P., & Srichana, T. (2009) · Journal of drug targeting · doi:10.3109/10611860903079462 · Cited by 42 · see citing works
Fighting tuberculosis: old drugs, new formulations
Blasi, P., Schoubben, A., Giovagnoli, S., Rossi, C. R., & Ricci, M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903130577 · Cited by 40 · see citing works
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Landa, G., Mendoza, G., Irusta, S., & Arruebo, M. (2025) · Advanced Materials · doi:10.1002/adma.202510355 · Cited by 43 · see citing works
Parikh, R. H., & Dalwadi, S. (2014) · Powder Technology · doi:10.1016/j.powtec.2014.04.077 · Cited by 39 · see citing works
Pulmonary delivery of pyrazinamide-loaded large porous particles
Pham, D.-D., Grégoire, N., Couet, W. R., Gueutin, C., Fattal, E., & Tsapis, N. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.021 · Cited by 39 · see citing works
Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis
Pandey, R., Sharma, S., & Khuller, G. K. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.01.002 · Cited by 39 · see citing works
Self-citationNano-antimicrobials: A new paradigm for combating mycobacterial resistance.
Minakshi, P., Ghosh, M., Brar, B., Kumar, R., Lambe, U., Ranjan, K., Prasad, G., & Manoj, J. (2019) · Current pharmaceutical design · doi:10.2174/1381612825666190620094041 · Cited by 18 · see citing works
Efficacy of Microencapsulated Rifampin in Mycobacterium tuberculosis -Infected Mice
Quenelle, D. C., Staas, J. K., Winchester, G. A., Barrow, E. L. W., & Barrow, W. W. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1144 · Cited by 38 · see citing works
Nano-based drug delivery optimization for tuberculosis treatment: A review
Dahanayake, M. H., & Jayasundera, A. C. A. (2020) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2020.106127 · Cited by 35 · see citing works
Pulmonary Drug Delivery: Medicines for Inhalation
Henning, A., Hein, S., Schneider, M., Bur, M., & Lehr, C. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00477-3_6 · Cited by 32 · see citing works
Novel technologies: A weapon against tuberculosis
Hari, B. V., Chitra, K., Bhimavarapu, R., Karunakaran, P., Muthukrishnan, N., & Rani, B. S. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.71887 · Cited by 32 · see citing works
A Sensitive HPLC Method for Determination of Isoniazid in Rat Plasma, Brain, Liver and Kidney
Bhandari, R. (2012) · Journal of Chromatography & Separation Techniques · doi:10.4172/2157-7064.1000128 · Cited by 31 · see citing works
Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment
Bekraki, A. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819811-7.00007-2 · Cited by 28 · see citing works
Bermudez, M. H., Martinez, E., Mora, M., Sagristá, M. L., & de Madariaga, M. A. (1999) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/s0927-7757(99)00131-4 · Cited by 25 · see citing works
Gaur, P. K., Mishra, S., Gupta, V. B., Rathod, M. S., Purohit, S., & Savla, B. A. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903410300 · Cited by 24 · see citing works
Carbon nanomaterials: a new way against tuberculosis
Maio, F. D., Palmieri, V., Spirito, M. D., Delogu, G., & Papi, M. (2019) · Expert Review of Medical Devices · doi:10.1080/17434440.2019.1671820 · Cited by 23 · see citing works
Lipid Microsphere Formulation Containing Rifampicin Targets Alveolar Macrophages
Takenaga, M., Ohta, Y., Tokura, Y., Hamaguchi, A., Igarashi, R., Disratthakit, A., & Doi, N. (2008) · Drug Delivery · doi:10.1080/10717540801952530 · Cited by 23 · see citing works
Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis
Sheikh, B. A., Bhat, B. A., Alshehri, B., Mir, R. A., Mir, W. R., Parry, Z. A., & Mir, M. A. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3201 · Cited by 20 · see citing works
Infectious Diseases: Need for Targeted Drug Delivery
Devarajan, P. V., Dawre, S., & Dutta, R. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_3 · Cited by 21 · see citing works
Verma, R. K., Singh, A. K., Mohan, M., Agrawal, A. K., & Misra, A. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.34 · Cited by 18 · see citing works
Treatment of mycobacterial infections
Barrow, W. W. (2001) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.20.1.1264 · Cited by 19 · see citing works
Truzzi, E., Meneghetti, F., Mori, M., Costantino, L., Iannuccelli, V., Maretti, E., Domenici, F., Castellano, C., Rogers, S. E., Capocefalo, A., et al. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.01.094 · Cited by 18 · see citing works
Merchant, Z., Buckton, G., Taylor, K. M. G., Stapleton, P. D., Saleem, I. Y., Zariwala, M. G., & Somavarapu, S. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160317142139 · Cited by 17 · see citing works
Synthesis and In-Vitro Antimycobacterial Studies of Cysteine Capped silver Nano-Particles
Varghese, M. V., Dhumal, R. S., Patil, S. S., Paradkar, A. R., & Khanna, P. K. (2009) · Synthesis and Reactivity in Inorganic Metal-Organic and Nano-Metal Chemistry · doi:10.1080/15533170903327869 · Cited by 16 · see citing works
Garhyan, J., Mohan, S., Rajendran, V., & Bhatnagar, R. (2020) · Pathogens · doi:10.3390/pathogens9050372 · Cited by 16 · see citing works
Mycobacterium tuberculosis Treatment Modalities and Recent Insights
Vijayrajratnam, S., Vinod, V., Varma, S., & Biswas, R. (2014) · Current Drug Delivery · doi:10.2174/1567201811666140619121728 · Cited by 16 · see citing works
Prolonged release from lipid nanoemulsions by modification of drug lipophilicity
Baumann, N., Baumgarten, J., Kunick, C., & Bunjes, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.021 · Cited by 15 · see citing works
Kundawala, A. J. (2014) · Scientia Pharmaceutica · doi:10.3797/scipharm.1307-03 · Cited by 15 · see citing works
Garcia‐Contreras, L., Sethuraman, V. V., Kazantseva, M., & Hickey, A. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081309 · Cited by 15 · see citing works
Disease guided optimization of the respiratory delivery of microparticulate formulations
Xie, Y., Zeng, P., & Wiedmann, T. S. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.269 · Cited by 14 · see citing works
Laghari, M., Darwis, Y., Memon, A. H., Khan, A. A., Abdulbaqi, I. M., & Assi, R. A. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i1.28 · Cited by 14 · see citing works
Oral Administration of Nanoparticles-Based TB Drugs
Magalhães, J., Vieira, A. C. C., Santos, S. G., Pinheiro, M., & Reis, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52725-5.00016-2 · Cited by 13 · see citing works
Lage, W. C., Sachs, D., Ribeiro, T. A. N., Tebaldi, M. L., de Moura, Y. D. R. S., Domingues, S. C., & Soares, D. C. F. (2021) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2021.111127 · Cited by 13 · see citing works
Wałęsa, R., Ptak, T., Siodłak, D., Kupka, T., & Broda, M. A. (2014) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.4064 · Cited by 11 · see citing works
Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections
Yıldırım, M., & Düzgüneş, N. (2025) · Antibiotics · doi:10.3390/antibiotics14070728 · Cited by 10 · see citing works
Isoniazid interaction with phosphatidylcholine-based membranes
Marques, A. V., Trindade, P. M., Marques, S., Brum, T. M. M., Harté, E., Rodrigues, M. O., D’Oca, M. G. M., da Silva, P. E. A., Pohlmann, A. R., Alves, I. D., et al. (2013) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2013.08.029 · Cited by 10 · see citing works
Lipid‐Based Drug Delivery Systems and Their Role in Infection and Inflammation Imaging
Karpuz, M., & Silindir‐Gunay, M. (2021) · doi:10.1002/9783527832095.ch15 · Cited by 9 · see citing works
Inhalation Drug Therapy: Emerging Trends in Nasal and Pulmonary Drug Delivery
Lalan, M. S., Tandel, H., Lalani, R., Patel, V., & Misra, A. R. (2019) · Springer eBooks · doi:10.1007/978-981-13-3642-3_9 · Cited by 8 · see citing works
Positively charged rifampicin-loaded microspheres for lung delivery
Pandit, S. S., Martin, C., & Alpar, H. O. (2005) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(05)50050-9 · Cited by 8 · see citing works
Nanotheranostic management of drug-resistant tuberculosis
Dustachkeer, V. N. A., Nirmal, C. R., Rajadas, S. E., Saadhali, S. A., Kannayan, S., & Padmanaban, V. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00004-8 · Cited by 7 · see citing works
Nanocarriers as Promising Drug Vehicles for the Management of Tuberculosis
Sharma, A. K., Kumar, R., Nishal, B., & Das, O. (2013) · BioNanoScience · doi:10.1007/s12668-013-0084-7 · Cited by 6 · see citing works
Polysaccharide installed lipid nanoparticles in targeted antituberculosis drug delivery applications
Banerjee, S., & Roy, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102553-6.00014-3 · Cited by 6 · see citing works
Recent Advances in Tuberculosis Research in India
Tyagi, A. K., & Dhar, N. (2003) · Advances in biochemical engineering, biotechnology · doi:10.1007/3-540-36488-9_7 · Cited by 6 · see citing works
Nanoformulations for the Therapy of Pulmonary Infections
Dhoble, S., Ghodake, V. N., Chogale, M. M., & Patravale, V. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46152-8.00020-2 · Cited by 5 · see citing works
Lankalapalli, S., Vemuri, V. D., Tenneti, V. S. V. K., & Guntaka, P. R. (2021) · Journal of Liposome Research · doi:10.1080/08982104.2021.2011912 · Cited by 5 · see citing works
Isoniazid Nano-drug Delivery Systems Targeting Macrophages for the Treatment of Tuberculosis
Vemula, S. L., & Gupta, M. T. (2022) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_40_22 · Cited by 4 · see citing works
Incorporation of Isoniazid into Liposomes with Different Lipid Composition
Sorokoumova, G. M., Селищева, А. А., Nm, M., Минина, А. С., & Швец, В. И. (2004) · Bulletin of Experimental Biology and Medicine · doi:10.1023/b:bebm.0000024375.65972.dd · Cited by 4 · see citing works
Peng, X., Wang, M., Chen, X.-X., Liu, J., Xiao, G.-H., & Liao, H.-L. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2135-y · Cited by 3 · see citing works
- Authors
- Deol, P., Khuller, G. K., & Joshi, K.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-06
- Volume
- 41
- Issue
- 6
- Pages
- 1211-1214
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC163888
- OpenAlex
- W1786188424
- Cited by
- 128
- References
- 23
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 9 · 2020: 5 · 2019: 11 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 1 · 2014: 13 · 2013: 12 · 2012: 3
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- isoniazid, rifampicin, PEGylated liposomes, liposomal drug delivery, Mycobacterium tuberculosis, tuberculosis chemotherapy, antitubercular agents, hepatotoxicity
- MeSH terms
- Animals, Antibiotics, Antitubercular, Antitubercular Agents, Dose-Response Relationship, Drug, Isoniazid, Liposomes, Lung, Mice, Inbred Strains, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Tuberculosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
